Suzhou, China, August 10, 2018 – JW Therapeutics and Suzhou Industrial Park (SIP) signed a strategic cooperation agreement today to locate JW Therapeutics’ first commercial manufacturing site in Suzhou BioBay. As a part of the agreement, JW Therapeutics will invest up to $30 million to establish a state of art, world-class commercial scale cGMP chimeric antigen receptor (CAR)-T manufacturing facility.
JW Therapeutics is a leading clinical stage cell therapy company in China focused on developing, manufacturing and commercializing breakthrough cell therapies for Chinese patients.? Earlier this year, JW Therapeutics completed a $100 million Series A financing led by Temasek, Sequoia Capital and YuanMing Capital. In June, JW Therapeutics received China National Drug Administration (CNDA) approval of an investigational new drug (IND) application for lead product JWCAR029 (a CAR-T cell product targeting CD19), intended to treat late-stage lymphoma and leukemia. It was the first IND approval by CNDA for a CAR-T cell product targeting CD19.
The establishment of the Suzhou facility will greatly enhance JW Therapeutics’ leading position and capability to produce world-class quality cell therapy products at commercial scale for its lead product and pipeline.
“JW Therapeutics aspires to become the leading cell therapy company in China. We want to bring together the most advanced cell therapy products and technology platforms in the world, complemented by our manufacturing, quality, regulatory and clinical development excellence to serve our patients in China and globally.” said Dr. James Li, CEO and co-founder of JW Therapeutics.
###
About JW Therapeutics
JW Therapeutics (Shanghai) Co. Ltd. is an innovative biotech company focused on the latest clinical cell therapy technology. It commits to “the development, transformation and promotion of breakthrough cell-based immunotherapies to save the lives of cancer patients, improve their quality of life and bring them new hope.” JW Therapeutics was co-founded by WuXiAppTec and Juno Therapeutics in February 2016.